1
|
Sumithaa C, Sugantharam K, Karanath-Anilkumar A, Munuswamy-Ramanujam G, Ganeshpandian M. RAPTA-coordinated polydiacetylene self-assembly: A chameleon-like prodrug with a dual-lock strategy for real-time release monitoring of metallodrug. Chem Commun (Camb) 2024; 60:9566-9569. [PMID: 39139058 DOI: 10.1039/d4cc03368j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2024]
Abstract
Herein, we report the first-ever design strategy of modifying RAPTA-C into a self-reporting prodrug candidate based on Ru-coordinated polydiacetylene self-assembly. This nanosystem exhibits a dual lock strategy that responds to visible light and pH-stimuli sequentially one by one with a concomitant color change for controlled RAPTA-C release and real-time release monitoring in human gastric cancer cells.
Collapse
Affiliation(s)
- Chezhiyan Sumithaa
- Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India.
| | - Karnan Sugantharam
- Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India.
| | - Aswathy Karanath-Anilkumar
- Molecular Biology and Immunobiology Division, Interdisciplinary Institute of Indian System of Medicine, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India
- Department of Biotechnology, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India
| | - Ganesh Munuswamy-Ramanujam
- Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India.
- Molecular Biology and Immunobiology Division, Interdisciplinary Institute of Indian System of Medicine, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India
| | - Mani Ganeshpandian
- Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India.
| |
Collapse
|
2
|
Pereira SAP, Romano-deGea J, Barbosa AI, Costa Lima SA, Dyson PJ, Saraiva MLMFS. Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers. Dalton Trans 2023; 52:11679-11690. [PMID: 37552495 PMCID: PMC10442743 DOI: 10.1039/d3dt02037a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 07/28/2023] [Indexed: 08/09/2023]
Abstract
Ruthenium-based complexes have been suggested as promising anticancer drugs exhibiting reduced general toxicity compared to platinum-based drugs. In particular, Ru(η6-arene)(PTA)Cl2 (PTA = 1,3,5-triaza-7-phosphaadamantane), or RAPTA, complexes have demonstrated efficacy against breast cancer by suppressing metastasis, tumorigenicity, and inhibiting the replication of the human tumor suppressor gene BRCA1. However, RAPTA compounds have limited cytotoxicity, and therefore comparatively high doses are required. This study explores the activity of a series of RAPTA-like ruthenium(II) arene compounds against MCF-7 and MDA-MB-231 breast cancer cell lines and [Ru(η6-toluene)(PPh3)2Cl]+ was identified as a promising candidate. Notably, [Ru(η6-toluene)(PPh3)2Cl]Cl was found to be remarkably stable and highly cytotoxic, and selective to breast cancer cells. The minor groove of DNA was identified as a relevant target.
Collapse
Affiliation(s)
- Sarah A P Pereira
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal.
- Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
| | - Jan Romano-deGea
- Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
| | - Ana Isabel Barbosa
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal.
| | - Sofia A Costa Lima
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal.
| | - Paul J Dyson
- Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
| | - M Lúcia M F S Saraiva
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal.
| |
Collapse
|
3
|
Fernández-Cortés M, Delgado-Bellido D, Bermúdez-Jiménez E, Paramio JM, O'Valle F, Vinckier S, Carmeliet P, Garcia-Diaz A, Oliver FJ. PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry. J Pathol 2023; 259:318-330. [PMID: 36484652 PMCID: PMC10107856 DOI: 10.1002/path.6043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 11/12/2022] [Accepted: 12/06/2022] [Indexed: 12/14/2022]
Abstract
Vasculogenic mimicry (VM) describes the ability of highly aggressive tumor cells to develop pseudovascular structures without the participation of endothelial cells. PARP1 is implicated in the activation of hypoxia-inducible factors, which are crucial in tumor neovascularization. We have explored the role of hypoxia and PARP inhibition in VM. In uveal melanoma xenografts, the PARP inhibitor olaparib improved in vivo pericyte coverage specifically of VM channels. This was concomitant with reduced metastasis in olaparib-treated VM+ tumors. PARP inhibition and hypoxia modulated melanoma tube formation in vitro, inducing a more sparse and regular tubular architecture. Whole-transcriptome profiling revealed that olaparib treatment under hypoxic conditions modulated the expression of genes implicated in vasculogenesis during tube formation, enhancing the endothelial-like phenotype of VM+ uveal melanoma cells. PARP inhibition, especially during hypoxia, upregulated PDGFβ, which is essential for pericyte recruitment. Our study indicates that PARP inhibitors may enhance the endothelial characteristics of VM+ cells, modulate pericyte coverage, and reduce metastatic spread in VM+ melanoma. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Collapse
Affiliation(s)
- Mónica Fernández-Cortés
- Instituto de Parasitología y Biomedicina López Neyra, CSIC, Centro de Investigación Biomédica en Red de Cáncer CIBERONC, Granada, Spain
| | - Daniel Delgado-Bellido
- Instituto de Parasitología y Biomedicina López Neyra, CSIC, Centro de Investigación Biomédica en Red de Cáncer CIBERONC, Granada, Spain
| | - Eloísa Bermúdez-Jiménez
- Instituto de Parasitología y Biomedicina López Neyra, CSIC, Centro de Investigación Biomédica en Red de Cáncer CIBERONC, Granada, Spain
| | - Jesús M Paramio
- Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Biomedical Research Institute I+12, University Hospital "12 de Octubre", Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Francisco O'Valle
- Department of Pathology, Faculty of Medicine, University of Granada (UGR), Granada, Spain
| | - Stefan Vinckier
- Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, & Department of Oncology and Leuven Cancer Institute (LKI), Leuven, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, & Department of Oncology and Leuven Cancer Institute (LKI), Leuven, Belgium.,Laboratory of Angiogenesis and Vascular Heterogeneity, Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - Angel Garcia-Diaz
- Instituto de Parasitología y Biomedicina López Neyra, CSIC, Centro de Investigación Biomédica en Red de Cáncer CIBERONC, Granada, Spain
| | - F Javier Oliver
- Instituto de Parasitología y Biomedicina López Neyra, CSIC, Centro de Investigación Biomédica en Red de Cáncer CIBERONC, Granada, Spain
| |
Collapse
|
4
|
Pereira SAP, Baptista L AC, Biancalana L, Marchetti F, Dyson PJ, Saraiva MLMFS. Automated approach for the evaluation of glutathione-S-transferase P1-1 inhibition by organometallic anticancer compounds. J Enzyme Inhib Med Chem 2022; 37:1527-1536. [PMID: 35635138 PMCID: PMC9176637 DOI: 10.1080/14756366.2022.2073443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- Sarah A. P. Pereira
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal
| | - A. Catarina Baptista L
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal
| | - Lorenzo Biancalana
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Pisa, Italy
| | - Fabio Marchetti
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Pisa, Italy
| | - Paul J. Dyson
- Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M. Lúcia M. F. S. Saraiva
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal
| |
Collapse
|
5
|
Pinessi D, Resovi A, Sangalli F, Morosi L, Zentilin L, Borsotti P, Carlessi E, Passoni A, Davoli E, Belotti D, Giavazzi R, Giacca M, Valbusa G, Berndt A, Zucchetti M, Taraboletti G. Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biol 2021; 103-104:22-36. [PMID: 34653669 DOI: 10.1016/j.matbio.2021.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 08/31/2021] [Accepted: 10/04/2021] [Indexed: 11/25/2022]
Abstract
The disorganized and inefficient tumor vasculature is a major obstacle to the delivery and efficacy of antineoplastic treatments. Antiangiogenic agents can normalize the tumor vessels, improving vessel function and boosting the distribution and activity of chemotherapy. The type III repeats (T3R) domain of thrombospondin-1 contains different potential antiangiogenic sequences. We therefore hypothesized that it might affect the tumor vasculature. Ectopic expression of the T3R domain by the tumor cells or by the host, or administration of recombinant T3R, delayed the in vivo growth of experimental tumors. Tumors presented marked reorganization of the vasculature, with abundant but smaller vessels, associated with substantially less necrosis. Mechanistically, the use of truncated forms of the domain, containing different active sequences, pointed to the FGF2/FGFR/ERK axis as a target for T3R activity. Along with reduced necrosis, the expression of T3R promoted tumor distribution of chemotherapy (paclitaxel), with a higher drug concentration and more homogeneous distribution, as assessed by HPLC and MALDI imaging mass spectrometry. T3R-expressing tumors were more responsive to paclitaxel and cisplatin. This study shows that together with its known role as a canonical inhibitor of angiogenesis, thrombospondin-1 can also remodel tumor blood vessels, affecting the morphological and functional properties of the tumor vasculature. The ability of T3R to reduce tumor growth and improve the response to chemotherapy opens new perspectives for therapeutic strategies based on T3R to be used in combination therapies.
Collapse
Affiliation(s)
- Denise Pinessi
- Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy
| | - Andrea Resovi
- Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy
| | - Fabio Sangalli
- Laboratory of Renal Biophysics, Department of Biomedical Engineering, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy
| | - Lavinia Morosi
- Cancer Clinical Pharmacology Unit, Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy
| | - Lorena Zentilin
- Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy
| | - Patrizia Borsotti
- Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy
| | - Elena Carlessi
- Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy
| | - Alice Passoni
- Center of Mass Spectrometry Research for Health and Environment and Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy
| | - Enrico Davoli
- Center of Mass Spectrometry Research for Health and Environment and Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy
| | - Dorina Belotti
- Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy
| | - Raffaella Giavazzi
- Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy
| | - Mauro Giacca
- School of Cardiovascular Medicine and Sciences, King's College London, London SE5 9NU, UK
| | | | - Alexander Berndt
- Section Pathology, Institute of Legal Medicine, Jena University Hospital, D-07747 Jena, Germany
| | - Massimo Zucchetti
- Cancer Clinical Pharmacology Unit, Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy
| | - Giulia Taraboletti
- Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy.
| |
Collapse
|
6
|
Aboura W, Batchelor LK, Garci A, Dyson PJ, Therrien B. Reactivity and biological activity of N,N,S-Schiff-base rhodium pentamethylcyclopentadienyl complexes. Inorganica Chim Acta 2020. [DOI: 10.1016/j.ica.2019.119265] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Recent progress in the development of organometallics for the treatment of cancer. Curr Opin Chem Biol 2019; 56:28-34. [PMID: 31812831 DOI: 10.1016/j.cbpa.2019.11.001] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 10/30/2019] [Accepted: 11/01/2019] [Indexed: 01/04/2023]
Abstract
From their early successes in medicine, organometallic compounds continue to attract interest as potential chemotherapeutics to treat a range of diseases. Here, we show from recent literature selected largely from the last two years that organometallics offer unique opportunities in medicine and, increasingly, a mechanistic-based approach is applied to their development, which has not always been the case.
Collapse
|
8
|
Rausch M, Dyson PJ, Nowak‐Sliwinska P. Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies. ADVANCED THERAPEUTICS 2019. [DOI: 10.1002/adtp.201900042] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Magdalena Rausch
- Molecular Pharmacology GroupSchool of Pharmaceutical Sciences, Faculty of SciencesUniversity of Lausanne and University of Geneva Rue Michel‐Servet 1, 1211 Geneva 4 Switzerland
| | - Paul J. Dyson
- Institute of Chemical Sciences and EngineeringEcole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne Switzerland
| | - Patrycja Nowak‐Sliwinska
- Molecular Pharmacology GroupSchool of Pharmaceutical Sciences, Faculty of SciencesUniversity of Lausanne and University of Geneva Rue Michel‐Servet 1, 1211 Geneva 4 Switzerland
- Translational Research Centre in Oncohaematology Geneva, Switzerland, 1211 Geneva 4 Switzerland
| |
Collapse
|
9
|
Ma T, Liu Y, Wu Q, Luo L, Cui Y, Wang X, Chen X, Tan L, Meng X. Quercetin-Modified Metal-Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX. ACS NANO 2019; 13:4209-4219. [PMID: 30933559 DOI: 10.1021/acsnano.8b09221] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
The development of multifunctional nanoscale radiosensitizers has attracted a tremendous amount of attention, which can enhance the radiosensitization of tumor tissues and reduce unnecessary damage to the surrounding organs. However, the persistent hypoxia environment within the tumor limits their applications in radiotherapy. In this paper, a stable nanocomposite was engineered to overcome the hypoxia properties by using 1,4-benzenedicarboxylic acid produced from a Zr-MOF as a carbonic anhydrase IX (CA IX) inhibitor and quercetin (QU) as a radiosensitizer. QU was encapsulated into the Zr-MOF structure to achieve a synergetic dual sensitization therapy. Zr-MOF-QU exhibits an excellent potential of radiotherapy sensitization characteristics in vitro and in vivo from the γ-H2AX immunofluorescence staining and colony assays. The mechanisms of alleviating hypoxia-induced resistance and sensitizing tumor tissues to improve cell apoptosis from radiation were found to suppress CA IX expressions by the decomposition product from Zr-MOF and boost the sensitivity by QU in radiation therapy. Moreover, there was no significant systemic toxicity during the treatment, and the therapeutic outcome was assessed in animal models. Therefore, our results demonstrate a promising cancer treatment approach in the radiation field.
Collapse
Affiliation(s)
- Tengchuang Ma
- Department of Nuclear Medicine , Harbin Medical University Cancer Hospital , Nangang District, Harbin , Heilongjiang Province 150086 , P.R. China
| | - Yunduo Liu
- Department of Gynecology , Harbin Medical University Cancer Hospital , Nangang District, Harbin , Heilongjiang Province 150086 , P.R. China
| | - Qiong Wu
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics, Technical Institute of Physics and Chemistry , Chinese Academy of Sciences , No. 29 East Road Zhongguancun , Beijing 100190 , P.R. China
| | - Lifang Luo
- Department of Gynecology , Harbin Medical University Cancer Hospital , Nangang District, Harbin , Heilongjiang Province 150086 , P.R. China
| | - Yali Cui
- Department of Nuclear Medicine , Harbin Medical University Cancer Hospital , Nangang District, Harbin , Heilongjiang Province 150086 , P.R. China
| | - Xinghua Wang
- Department of Nuclear Medicine , Harbin Medical University Cancer Hospital , Nangang District, Harbin , Heilongjiang Province 150086 , P.R. China
| | - Xiuwei Chen
- Department of Gynecology , Harbin Medical University Cancer Hospital , Nangang District, Harbin , Heilongjiang Province 150086 , P.R. China
| | - Longfei Tan
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics, Technical Institute of Physics and Chemistry , Chinese Academy of Sciences , No. 29 East Road Zhongguancun , Beijing 100190 , P.R. China
| | - Xianwei Meng
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics, Technical Institute of Physics and Chemistry , Chinese Academy of Sciences , No. 29 East Road Zhongguancun , Beijing 100190 , P.R. China
| |
Collapse
|
10
|
Chen Z, Niu M, Chen G, Wu Q, Tan L, Fu C, Ren X, Zhong H, Xu K, Meng X. Oxygen Production of Modified Core-Shell CuO@ZrO 2 Nanocomposites by Microwave Radiation to Alleviate Cancer Hypoxia for Enhanced Chemo-Microwave Thermal Therapy. ACS NANO 2018; 12:12721-12732. [PMID: 30512923 DOI: 10.1021/acsnano.8b07749] [Citation(s) in RCA: 71] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
There are acknowledged risks of metastasis of cancer cells and obstructing cancer treatment from hypoxia. In this work, we design a multifunctional nanocomposite for treating hypoxia based on the oxygen release capability of CuO triggered by microwave (MW). Core-shell CuO@ZrO2 nanocomposites are prepared by confining CuO nanoparticles within the cavities of mesoporous ZrO2 hollow nanospheres. 1-Butyl-3-methylimidazolium hexafluorophosphate (IL) is loaded to the CuO@ZrO2 nanocomposites for improving microwave thermal therapy (MWTT). 1-Tetradecanol (PCM) is introduced to regulate the release of chemotherapeutic drugs of doxorubicin (DOX). Thus, the IL-DOX-PCM-CuO@ZrO2 multifunctional (IDPC@Zr) nanocomposites are obtained. Finally, IDPC@Zr nanocomposites are modified by monomethoxy polyethylene glycol sulfhydryl (mPEG-SH, 5 kDa) (IDPC@Zr-PEG nanocomposites). IDPC@Zr-PEG nanocomposites can produce oxygen in the tumor microenvironment during the course of tumor treatment, thereby alleviating the hypoxic state and improving the therapeutic effect. In vivo antitumor experiments demonstrate a very high tumor inhibition rate of 92.14%. In addition, computed tomography (CT) imaging contrast of the nanocomposites can be enhanced due to the high atomic number of Zr. Therefore, IDPC@Zr-PEG nanocomposites can be applied for monitoring the tumor-treatment process in real time. This combined therapy offers many opportunities, such as the production of oxygen from CuO nanoparticles by MW to alleviate hypoxia, the enhancement of combined treatment of MWTT and chemotherapy, and the potential application of CT imaging to visualize the treatment process, which therefore provides a promising method for the clinical treatment of tumors in the future.
Collapse
Affiliation(s)
- Zengzhen Chen
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Number 29 East Road Zhongguancun , Beijing 100190 , PR China
- University of the Chinese Academy of Sciences , Beijing 100049 , PR China
| | - Meng Niu
- Department of Radiology , First Hospital of China Medical University; Key Laboratory of Diagnostic Imaging and Interventional Radiology in Liaoning Province , Shenyang 110001 , PR China
| | - Gen Chen
- School of Materials Science and Engineering , Central South University , Changsha , Hunan 410083 , PR China
| | - Qiong Wu
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Number 29 East Road Zhongguancun , Beijing 100190 , PR China
| | - Longfei Tan
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Number 29 East Road Zhongguancun , Beijing 100190 , PR China
| | - Changhui Fu
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Number 29 East Road Zhongguancun , Beijing 100190 , PR China
| | - Xiangling Ren
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Number 29 East Road Zhongguancun , Beijing 100190 , PR China
| | - Hongshan Zhong
- Department of Radiology , First Hospital of China Medical University; Key Laboratory of Diagnostic Imaging and Interventional Radiology in Liaoning Province , Shenyang 110001 , PR China
| | - Ke Xu
- Department of Radiology , First Hospital of China Medical University; Key Laboratory of Diagnostic Imaging and Interventional Radiology in Liaoning Province , Shenyang 110001 , PR China
| | - Xianwei Meng
- Laboratory of Controllable Preparation and Application of Nanomaterials, Key Laboratory of Cryogenics , Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Number 29 East Road Zhongguancun , Beijing 100190 , PR China
| |
Collapse
|